Since the beginning of cancer research, it is well known that cells within a tumor exhibit morphological and functional heterogeneity showing different states of differentiation, proliferative capacities and sensitivity to treatments. Recent data indicate that there is yet another level of heterogeneity. A subset of cells within the tumor mass differs from the rest of cells in its increased ability to initiate and recapitulate the tumor of the patient when inoculated in mice. These cells, also called cancer stem cells or cancer initiating cells (CICs), exhibit stem-cell like characteristics and are not only considered to be responsible for tumor initiation but for tumor propagation, recurrence, chemo-and radio-resistance and, in certain cases, metastasis. All these characteristics indicate that CICs are crucial therapeutic targets and suggest that the understanding of the molecular mechanisms involved in CIC biology is critical in order to design rational and successful therapies. [1] [2] [3] Several signal transduction pathways have been implicated in the control of CICs including the Wnt, Hh and Notch pathways. Recently, TGFβ family members have also been involved in the regulation of CIC biology. The TGFβ family of cytokines includes the TGFβs, BMPs, Nodal, Activins and GDFs and is involved in the regulation of embryonic development and tissue homeostasis. [4] [5] [6] Ligands of the TGFβ family initiate signal transduction through ligand-receptor interactions that converge to nuclear accumulation of transcriptionally active Smads. In general and with exceptions in some cell types, TGFβs, Activins and Nodal signal through Smad2 and 3 whereas BMPs and GDFs signal through Smad1, Smad5 and Smad8. 4, 5 BMP has been shown to inhibit proliferation and induce differentiation of CICs in glioblastoma multiforme (GBM). 7, 8 However, not all glioblastoma initiating cells (GICs) respond to BMP. Only GICs from tumors with no methylation of the BMP receptor 1b (BMPR1b) gene differentiate and stop proliferating when treated with BMP. 8 Although the mediators of the BMP effect are not identified, BMP is considered a putative therapeutic effector targeting GICs. 7, 8 On the other hand, TGFβ induces the converse effect. TGFβ promotes GIC self-renewal and prevents differentiation enhancing the oncogenic capacity of GICs, Figure 1 . 9 These functionally opposed responses to TGFβ and BMP are not an uncommon phenomenon in cell differentiation processes. 10 TGFβ has an important role in glioma.
11,12 TGFβ is highly active in aggressive gliomas and a high level of phospho-Smad2 is a poor prognosis factor in patients indicating that TGFβ is involved in tumor progression. 12 The effect of TGFβ on GIC self-renewal is part of the oncogenic response to TGFβ in addition to the capacity of TGFβ to induce proliferation, inmunosuppression, invasion and angiogenesis. 6 The regulation of GIC self-renewal by TGFβ is mediated by LIF. TGFβ induces LIF transcription via an activated Smad complex that binds to the LIF promoter and LIF, in turn, promotes self-renewal and prevents differentiation of GICs. 9 In human patients, LIF is highly expressed in tumors with high levels of TGFβ2, 9 and, moreover, LIF is one of the genes present in gene expression signatures that identify a subclass of human GBMs with a mesenchymal phenotype. 13 The mesenchymal GBM subclass is the most aggressive of all subclasses.
LIF is a member of the IL6 family of cytokines and signals through an heterodimeric receptor complex formed by the glycoprotein 130 (gp130) and the LIF receptor (LIFR) inducing the JAK-STAT pathway. Interestingly, IL6 itself induces GIC proliferation and survival and blockade of IL6 inhibits tumor initiation. 14 Thus, both members of the IL6 family, LIF and IL6, share the same effect on GICs. Of relevance, IL6 is also induced by TGFβ in GBM (Seoane J, et al. unpublished results) indicating that IL6 might also be a mediator of the induction of GIC self-renewal by TGFβ, Figure 1 .
The effect of TGFβ family members on GICs has a parallelism in normal human embryonic stem cells (ESCs). TGFβ, Activins and Nodal promote human ESC self-renewal whereas BMPs promote cell differentiation. [15] [16] [17] Recently, it has been shown that the effect of TGFβ/Activin in human ESCs is in part mediated by the Smad-dependent induction of Nanog. 18 In addition, LIF is a well studied inducer of mouse ESC self-renewal. All these results indicate that GICs may recapitulate similar mechanisms of self-renewal regulation to the ones found in normal stem cells.
The role of TGFβ and BMP in CICs from other tumor types besides GBM has not been fully studied. However, TGFβ has been implicated in the regulation of cells with stem cell-like characteristics in breast cancer. The TGFβ-mediated induction of an epithelial-mesenchymal transition (EMT) in neoplastic mammary epithelial cell populations has been shown to result in the enrichment of a CD44 high / CD24 low cell population. 19, 20 This cell population presents stem cell-like characteristics including the capacity to initiate tumors and the resistance to chemotherapy. 19, 21 Further studies are needed to show whether the mechanisms that regulate GIC self-renewal have a parallel in tGFβ and cancer initiating cells a differentiating factor only in the subset of CICs with no epigenetic silencing of the BMPR1b gene. 8 Another level of complexity comes from the possibility that the same tumor may contain different CICs with heterogeneous characteristics. These concepts imply that CICs within each tumor should be well characterized prior to treatment with a particular compound. Further work is required to obtain CIC specific markers in order to study the characteristics and regulation of this cell compartment.
the CD44
high /CD24 low cell population in breast tumors.
Based on the definition of CICs, this cell population is the critical therapeutic target in cancer. The data reviewed here indicate that compounds that inhibit TGFβ could be effective against CICs. The inhibition of TGFβ could decrease the CIC pool in tumors and might prevent tumor recurrence, resistance to chemo and radio-therapies, and possibly metastasis. This is of great relevance in the context of anti-TGFβ therapies currently being developed and tested in clinical trials. 22 However, it is important to note that different tumors might have CICs with different molecular characteristics and with different responses to treatments. This is exemplified by the fact that BMP is 
